A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients
While limited by a small sample size, this descriptive study showed that GLP1-RAs did not trigger flares above expected background rates and were associated with significantly decreased BMI. Future studies exploring the potential benefits of GLP1-RAs in patients with SLE are warranted.
Authors
- Amit Saxena (ORCID: https://orcid.org/0000-0003-0098-1083)
- Brooke Cohen
- Mala Masson
- H. Michael Belmont (ORCID: https://orcid.org/0000-0003-3389-2976)
- Peter Izmirly (ORCID: https://orcid.org/0000-0001-5445-2182)
- Heather T. Gold (ORCID: https://orcid.org/0000-0002-5896-0499)
- Jill P. Buyon (ORCID: https://orcid.org/0000-0002-3852-7129)
- Philip M. Carlucci (ORCID: https://orcid.org/0000-0002-9729-4572)
Institutions
- New York University (US)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1093/rheumatology/keae547
- Citations
- 10
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 4.70
Funders
- U.S. Department of Health and Human Services
- National Institutes of Health
- Centers for Disease Control and Prevention